Page last updated: 2024-08-16

thalidomide and pemetrexed

thalidomide has been researched along with pemetrexed in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD	1

Reviews

1 review(s) available for thalidomide and pemetrexed

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for thalidomide and pemetrexed

Article	Year
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chi-Square Distribution; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Palliative Care; Pemetrexed; Pleural Neoplasms; Proportional Hazards Models; Thalidomide; Time Factors; Treatment Outcome	2013

Article

Year

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.

The Lancet. Oncology, 2013, Volume: 14, Issue:6

Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chi-Square Distribution; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Palliative Care; Pemetrexed; Pleural Neoplasms; Proportional Hazards Models; Thalidomide; Time Factors; Treatment Outcome

2013

Other Studies

1 other study(ies) available for thalidomide and pemetrexed

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023